A Cell-based Model to Study Mechanisms of Endothelial-dependent Thrombin Generation in Response to Inflammation and Its Modulation by Hydroxychloroquine

Overview

Journal Res Pract Thromb Haemost

Publisher Elsevier

Date 2025 Jan 29

PMID 39877523

Authors

Deepa J Arachchillage

Golzar Mobayen

Mike Laffan

Anna M Randi

Josefin Ahnstrom

Charis Pericleous

Affiliations

Soon will be listed here.

Abstract

Background: Inflammation is a driver of thrombosis, but the phenomenon of thromboinflammation has been defined only recently, bringing together the multiple pathways involved. models can support the development of new therapeutics targeting the endothelium and also assess the existing immunomodulatory drugs, such as hydroxychloroquine, in modulating the inflammation-driven endothelial prothrombotic phenotype.

Objectives: To develop a model for thrombin generation (TG) on the surface of human endothelial cells (ECs) to assess pro/antithrombotic properties in response to inflammation. Furthermore, to elucidate the mechanisms of TG regulation and its modulation by immunomodulatory therapies.

Methods: Cytokine-induced (tumor necrosis factor [TNF]-α, interleukin [IL]-1β, and interferon-γ) effects on ECs isolated from umbilical veins or human aortic tissue were assessed using calibrated automated thrombography in platelet-poor plasma. The expression of key coagulant and inflammatory regulators was measured at the mRNA level. Tissue factor (TF) protein levels were further assessed by flow cytometry.

Results: Endothelial stimulation with TNF-α or IL-1β caused ECs to trigger TG without the addition of exogenous TF, with higher TG observed after 6 hours of stimulation than 24 hours. IL-1β induced higher peak thrombin (170 ± 5.9 nM vs 115 ± 4.9 nM), endogenous thrombin potential (1632 ± 35 nM ∗ min vs 1370 ± 23 nM ∗ min) presented as mean ± SD, and TF expression (∼2.8-fold higher) compared with TNF-α at 6 hours. Interferon-γ stimulation failed to induce TG and TF expression. The immunomodulatory drug, hydroxychloroquine, reduced cytokine-induced TG and downregulated TF expression.

Conclusion: We provide detailed optimization of a robust model to assess the induction of an inflammation-driven endothelial prothrombotic phenotype that is also sensitive to immunomodulatory therapies, providing a tool for investigating mechanisms of disease and new drugs.

References

Gierula M, Ahnstrom J . Anticoagulant protein S-New insights on interactions and functions. J Thromb Haemost. 2020; 18(11):2801-2811. DOI: 10.1111/jth.15025. View

Billoir P, Miranda S, Damian L, Richard V, Benhamou Y, Le Cam Duchez V . Development of a thrombin generation test in cultured endothelial cells: Evaluation of the prothrombotic effects of antiphospholipid antibodies. Thromb Res. 2018; 169:87-92. DOI: 10.1016/j.thromres.2018.07.021. View

Randi A, Jones D, Peghaire C, Arachchillage D . Mechanisms regulating heterogeneity of hemostatic gene expression in endothelial cells. J Thromb Haemost. 2023; 21(11):3056-3066. DOI: 10.1016/j.jtha.2023.06.024. View

Mackman N, Taubman M . Does tissue factor expression by vascular smooth muscle cells provide a link between C-reactive protein and cardiovascular disease?. Arterioscler Thromb Vasc Biol. 2008; 28(4):601-3. DOI: 10.1161/ATVBAHA.108.165050. View

Schmaier A, Hurtado G, Manickas-Hill Z, Sack K, Chen S, Bhambhani V . Tie2 activation protects against prothrombotic endothelial dysfunction in COVID-19. JCI Insight. 2021; 6(20). PMC: 8564889. DOI: 10.1172/jci.insight.151527. View

Klein S, Flanagan K . Sex differences in immune responses. Nat Rev Immunol. 2016; 16(10):626-38. DOI: 10.1038/nri.2016.90. View

Aksu K, Donmez A, Keser G . Inflammation-induced thrombosis: mechanisms, disease associations and management. Curr Pharm Des. 2012; 18(11):1478-93. DOI: 10.2174/138161212799504731. View

Arachchillage D, Laffan M, Pericleous C . Hydroxychloroquine as an Immunomodulatory and Antithrombotic Treatment in Antiphospholipid Syndrome. Int J Mol Sci. 2023; 24(2). PMC: 9866802. DOI: 10.3390/ijms24021331. View

Yang B, Gozzi P, Sullivan J . Pharmacokinetics of Anakinra in Subjects of Heavier vs. Lighter Body Weights. Clin Transl Sci. 2019; 12(4):371-378. PMC: 6662383. DOI: 10.1111/cts.12622. View

10.

Del Valle D, Kim-Schulze S, Huang H, Beckmann N, Nirenberg S, Wang B . An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med. 2020; 26(10):1636-1643. PMC: 7869028. DOI: 10.1038/s41591-020-1051-9. View

11.

Libby P, Simon D . Inflammation and thrombosis: the clot thickens. Circulation. 2001; 103(13):1718-20. DOI: 10.1161/01.cir.103.13.1718. View

12.

Ahnstrom J, Andersson H, Canis K, Norstrom E, Yu Y, Dahlback B . Activated protein C cofactor function of protein S: a novel role for a γ-carboxyglutamic acid residue. Blood. 2011; 117(24):6685-93. DOI: 10.1182/blood-2010-11-317099. View

13.

Mast A . Tissue Factor Pathway Inhibitor: Multiple Anticoagulant Activities for a Single Protein. Arterioscler Thromb Vasc Biol. 2015; 36(1):9-14. PMC: 4690769. DOI: 10.1161/ATVBAHA.115.305996. View

14.

Geenen I, Molin D, van den Akker N, Jeukens F, Spronk H, Schurink G . Endothelial cells (ECs) for vascular tissue engineering: venous ECs are less thrombogenic than arterial ECs. J Tissue Eng Regen Med. 2012; 9(5):564-76. DOI: 10.1002/term.1642. View

15.

Durcan L, Clarke W, Magder L, Petri M . Hydroxychloroquine Blood Levels in Systemic Lupus Erythematosus: Clarifying Dosing Controversies and Improving Adherence. J Rheumatol. 2015; 42(11):2092-7. PMC: 4630115. DOI: 10.3899/jrheum.150379. View

16.

Korth-Bradley J, Rubin A, Hanna R, Simcoe D, Lebsack M . The pharmacokinetics of etanercept in healthy volunteers. Ann Pharmacother. 2000; 34(2):161-4. DOI: 10.1345/aph.19126. View

17.

Chen L, Deng H, Cui H, Fang J, Zuo Z, Deng J . Inflammatory responses and inflammation-associated diseases in organs. Oncotarget. 2018; 9(6):7204-7218. PMC: 5805548. DOI: 10.18632/oncotarget.23208. View

18.

Theofilis P, Sagris M, Oikonomou E, Antonopoulos A, Siasos G, Tsioufis C . Inflammatory Mechanisms Contributing to Endothelial Dysfunction. Biomedicines. 2021; 9(7). PMC: 8301477. DOI: 10.3390/biomedicines9070781. View

19.

Jackson S, Darbousset R, Schoenwaelder S . Thromboinflammation: challenges of therapeutically targeting coagulation and other host defense mechanisms. Blood. 2019; 133(9):906-918. DOI: 10.1182/blood-2018-11-882993. View

20.

Ebert J, Wilgenbus P, Teiber J, Jurk K, Schwierczek K, Dohrmann M . Paraoxonase-2 regulates coagulation activation through endothelial tissue factor. Blood. 2018; 131(19):2161-2172. DOI: 10.1182/blood-2017-09-807040. View